SDRI 2017 is a multi-disciplinary scientific conference focused on Solutions for Drug-Resistant Infections. It will bring together leading scientific, medical and industry experts to discuss new solutions and an integrated ‘one health’ approach to the global challenge of drug-resistant pathogens.
The inaugural conference will take place at the Brisbane Convention and Exhibition Centre in Australia from 3 - 5 April, 2017. The program is expected to attract 400 international participants and will provide a fantastic forum for senior research leaders, key industry representatives, students and early career researchers working in the field to network and discuss new ways to solve the global challenge of drug-resistant infections in human and animal health.
Our goal for SDRI 2017 is to lead a concerted discussion to set three priorities and guide research efforts towards global solutions for drug resistance research.
International keynote speakers confirmed:
- Professor Dame Sally Davies, Chief Medical Officer for England
- Professor Ramanan Laxminarayan, Vice President, Research and Policy (Public Health Foundation of India (PHFI) and Director Center for Disease Dynamics, Economics & Policy (CDDEP), Washington DC
- Dr Jennifer Leeds, Head of Antibacterial Discovery, Novartis
- Professor Man-Wah Tam, Director, Infectious Disease, Genentech
- Dr Line Matthiessen-Guyader, Head of Unit, Research Directorate-General, Biotechnology, Agriculture and Food Research, European Commission
- Antimicrobial drug discovery
- Improvements to existing anti-infective agents and repurposing
- New Drug Targets
- Alternate therapies
- Navigating the pipeline
- International Models and Funding
- Vector control and vaccines
We look forward to welcoming you to Queensland in 2017.
Professor Matthew Cooper Co-Chair SDRI 2017
Professor Jian Li Co-Chair SDRI 2017
The conference will be organised by The University of Queensland’s Institute for Molecular Bioscience Centre for Superbug Solutions, where finding new therapeutics, diagnosis and monitoring of drug-resistant infections is one of our strategic priorities.